Emergent Biosolutions (EBS) : Traders are bullish on Emergent Biosolutions (EBS) as it has outperformed the S&P 500 by a wide margin of 0.17% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.37%, relative to the S&P 500. The stock has risen by 2.92% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.86% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 0.68% and the 50-Day Moving Average is 5.83%.The 200 Day SMA reached 21.97% Emergent BioSolutions, Inc. has dropped 29.46% during the last 3-month period . Year-to-Date the stock performance stands at -31.29%.
Emergent Biosolutions (EBS) : The most positive equity analysts on Emergent Biosolutions (EBS) expects the shares to touch $47, whereas, the least positive believes that the stock will trade at $33 in the short term. The company is covered by 2 Wall Street Brokerage Firms. The average price target for shares are $40 with an expected fluctuation of $9.9 from the mean.
For the current week, the company shares have a recommendation consensus of Buy. Emergent Biosolutions (NYSE:EBS): The stock opened at $27.39 and touched an intraday high of $27.69 on Friday. During the day, the stock corrected to an intraday low of $26.96, however, the bulls stepped in and pushed the price higher to close in the green at $27.49 with a gain of 0.15% for the day. The total traded volume for the day was 1,097,818. The stock had closed at $27.49 in the previous trading session.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Companys two operating divisions include Biodefense and Biosciences. The Companys Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) threats. The Biodefense divisions marketed products are BioThrax; BAT; Anthrasil; VIGIV, and RSDL. The Biodefense division investigational stage product candidates include NuThrax, PreviThrax, GC-072 and other biodefense product candidates. The Biosciences divisions marketed products are WinRho SDF, HepaGam B, VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY, ES414 and otlertuzumab.